Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

Conditions

Chronic Lymphocytic Leukemia

What is the purpose of this trial?

This study will determine whether or not Lenalidomide improves effectiveness of treatment for chronic lymphocytic leukemia following chemotherapy with two drugs commonly used to treat the disease (bendamustine and rituximab).



Participation Guidelines

Age:
18 Years - 90 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Celgene Corporation
Yale University
Dates:
March 2012
Last Updated:
October 22, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01465230